• Stanislaw Schmidt, Lars Tramsen, Andreas Schneider, Ada Balan, and Thomas Lehrnbecher.
• Pediatric Hematology and Oncology, Johann Wolfgang Goethe-University, Frankfurt, Germany.
• Mycoses. 2014 Dec 1;57 Suppl 3:8-12.

AbstractMucormycoses remain a serious complication in patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). In these patients, mortality rates of mucormycosis reach up to 90%, which is due, at least in part, to the severe and prolonged immunosuppression after transplantation. Although prolonged neutropaenia is one of the most important risk factors for mucormycosis, other cell populations, such as CD4(+) T cells may also provide critical defence mechanisms against this infection. The management of mucormycosis includes antifungal therapy, surgery and, most importantly, the control of the underlying predisposing conditions, such as the correction of an impaired immune system. Here, we review the current data of granulocytes, antifungal T cells and natural killer cells regarding their activity against mucormycetes and regarding a potential immunotherapeutic approach. It is hoped that further animal studies and clinical trials assessing immunotherapeutic strategies will ultimately improve the poor prognosis of allogeneic HSCT recipients suffering from mucormycosis.© 2014 Blackwell Verlag GmbH.

18 keywords...

hide…